ERYP: AI 评分 51/100 — AI 分析 (4月 2026)

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on developing red blood cell-based therapeutics for cancer and orphan diseases. Their lead product, eryaspase, targets pancreatic cancer, triple-negative breast cancer, and acute lymphoblastic leukemia.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company specializing in red blood cell-based therapeutics for oncology and orphan diseases, with a focus on its lead product candidate, eryaspase, currently in Phase 3 clinical development for second-line pancreatic cancer, positioning it within the competitive biotechnology landscape.

ERYP是做什么的？

ERYTECH Pharma S.A., established in 2004 and headquartered in Lyon, France, is a biopharmaceutical company dedicated to developing innovative therapies for cancer and orphan diseases. The company's core technology revolves around encapsulating therapeutic enzymes within red blood cells to enhance their efficacy and reduce systemic side effects. ERYTECH's lead product candidate, eryaspase, is a red blood cell-encapsulated L-asparaginase, designed to starve cancer cells of asparagine, an essential amino acid. Eryaspase is currently in Phase 3 clinical development for the treatment of second-line pancreatic cancer. Additionally, eryaspase is in Phase 2 clinical trials for triple-negative breast cancer and second-line acute lymphoblastic leukemia. Beyond eryaspase, ERYTECH is also developing erymethionase, a preclinical product candidate that utilizes red blood cells to deliver methionine-?-lyase, targeting methionine-dependent cancers. The company operates primarily in France and the United States, focusing on areas with significant unmet medical needs in oncology. With a team of 49 employees, ERYTECH is committed to advancing its pipeline and bringing novel therapies to patients with limited treatment options.

ERYP的投资论点是什么？

ERYTECH Pharma S.A. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful completion of the Phase 3 clinical trial for eryaspase in second-line pancreatic cancer, with potential FDA approval and subsequent commercialization. Positive results could significantly increase the company's market capitalization, currently at $0.05 billion. The company's negative profit margin of -1771.3% highlights its reliance on clinical trial outcomes and future revenue generation. Key catalysts include the progression of eryaspase through clinical trials and potential partnerships for commercialization. However, the investment is subject to significant risks, including clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The high beta of 2.13 indicates significant volatility.

ERYP在哪个行业运营？

ERYTECH Pharma S.A. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. ERYTECH's red blood cell-based therapeutic approach offers a unique delivery system that could differentiate it from competitors. However, the company faces competition from established pharmaceutical companies with greater resources and broader pipelines. The success of ERYTECH depends on its ability to navigate the regulatory landscape, secure funding, and demonstrate the clinical efficacy of its product candidates.

Biotechnology

Healthcare

ERYP有哪些增长机遇？

Expansion into New Therapeutic Areas: ERYTECH has the opportunity to leverage its red blood cell encapsulation technology to develop therapies for other types of cancer and orphan diseases. The market for orphan drugs is particularly attractive due to regulatory incentives and reduced competition. By expanding its pipeline, ERYTECH can diversify its revenue streams and reduce its reliance on eryaspase. The timeline for this expansion depends on the company's ability to secure funding and advance new product candidates through preclinical and clinical development. The market size for orphan drugs is projected to reach $262 billion by 2028.
Partnerships and Collaborations: ERYTECH can pursue partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships can provide access to funding, expertise, and distribution networks. The timeline for securing partnerships depends on the company's ability to demonstrate the value of its technology and product candidates. The global pharmaceutical market is estimated to be worth over $1.4 trillion.
Geographic Expansion: ERYTECH can expand its operations into new geographic markets, such as Europe and Asia, to increase its market reach and revenue potential. The European market for cancer therapeutics is particularly attractive due to its large population and well-developed healthcare infrastructure. The timeline for geographic expansion depends on the company's ability to navigate regulatory requirements and establish a commercial presence in new markets. The European pharmaceutical market is the second largest in the world, valued at over $400 billion.
Advancement of Erymethionase: ERYTECH's preclinical product candidate, erymethionase, represents a significant growth opportunity. By advancing erymethionase through preclinical and clinical development, ERYTECH can expand its pipeline and target methionine-dependent cancers. The timeline for this advancement depends on the company's ability to secure funding and demonstrate the safety and efficacy of erymethionase. The market for methionine-dependent cancer therapies is estimated to be worth billions of dollars.
Orphan Drug Designation and Accelerated Approval Pathways: ERYTECH can leverage orphan drug designation and accelerated approval pathways to expedite the development and commercialization of its product candidates. Orphan drug designation provides regulatory incentives, such as market exclusivity and tax credits, while accelerated approval pathways allow for faster approval based on surrogate endpoints. The timeline for obtaining orphan drug designation and accelerated approval depends on the company's ability to meet the regulatory requirements. The orphan drug market is projected to grow significantly in the coming years.

Eryaspase is in Phase 3 clinical development for second-line pancreatic cancer, representing a significant potential market opportunity.
The company has a gross margin of 100.0%, reflecting the nature of its biopharmaceutical business model.
ERYTECH's market capitalization is $0.05 billion, indicating its small-cap status within the biotechnology industry.
The company's profit margin is -1771.3%, highlighting its current lack of profitability due to ongoing research and development expenses.
ERYTECH's beta is 2.13, indicating higher volatility compared to the overall market.

ERYP提供哪些产品和服务？

Develops red blood cell-based therapeutics for cancer.
Focuses on treating pancreatic cancer, triple-negative breast cancer, and acute lymphoblastic leukemia.
Utilizes a proprietary technology to encapsulate therapeutic enzymes within red blood cells.
Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
Seeks regulatory approval for its product candidates from health authorities.
Aims to commercialize its therapies to improve patient outcomes.

ERYP如何赚钱？

Develops and patents novel red blood cell-based therapeutics.
Conducts clinical trials to demonstrate efficacy and safety.
Seeks regulatory approval for its products.
Out-licenses or commercializes approved therapies.

Patients with cancer and orphan diseases.
Oncologists and hematologists who prescribe the company's therapies.
Hospitals and cancer centers that administer the company's therapies.
Pharmaceutical companies that may partner with ERYTECH for development and commercialization.

Proprietary red blood cell encapsulation technology.
Patent protection for its product candidates.
Clinical data supporting the efficacy and safety of its therapies.
Orphan drug designation for certain indications.

什么因素可能推动ERYP股价上涨？

Upcoming: Data readout from the Phase 3 clinical trial of eryaspase in second-line pancreatic cancer expected in Q4 2026.
Upcoming: Initiation of a Phase 2 clinical trial of eryaspase in a new cancer indication planned for Q2 2027.
Ongoing: Continued enrollment of patients in the Phase 2 clinical trial of eryaspase in triple-negative breast cancer.
Ongoing: Potential for securing partnerships with larger pharmaceutical companies for the development and commercialization of eryaspase.

ERYP的主要风险是什么？

Potential: Failure of the Phase 3 clinical trial of eryaspase in second-line pancreatic cancer.
Potential: Regulatory delays or rejection of eryaspase by health authorities.
Ongoing: Competition from established pharmaceutical companies with greater resources and broader pipelines.
Ongoing: Dependence on the success of eryaspase, with limited diversification of the product pipeline.
Potential: Difficulty in securing funding to support ongoing research and development activities.

ERYP的核心优势是什么？

Proprietary red blood cell encapsulation technology.
Lead product candidate in Phase 3 clinical development.
Potential for orphan drug designation.
Experienced management team.

ERYP的劣势是什么？

Limited financial resources.
High dependence on the success of eryaspase.
Lack of commercial infrastructure.
Negative profit margin.

ERYP有哪些机遇？

Expansion into new therapeutic areas.
Partnerships with larger pharmaceutical companies.
Geographic expansion.
Advancement of erymethionase.

ERYP面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from established pharmaceutical companies.
Patent infringement.

ERYP的竞争对手是谁？

AlloVir, Inc. — Focuses on cell therapies for viral diseases. — (ALVR)
bluebird bio, Inc. — Develops gene therapies for severe genetic diseases. — (BLUE)
Cerecor Inc. — Develops therapies for rare diseases and neurological disorders. — (CERC)
GRI Bio, Inc. — Focuses on immune cell therapies. — (GRNA)
Kronos Bio, Inc. — Develops therapies targeting dysregulated transcription in cancer. — (KRON)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Gil Beyen
Headquarters: Lyon, FR
Employees: 49
Founded: 2016

AI Insight

AI analysis pending for ERYP

ADR Level: 2
ADR Ratio: 1:1

常见问题

What does ERYTECH Pharma S.A. do?

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company specializing in the development of innovative red blood cell-based therapeutics for cancer and orphan diseases. Their core technology involves encapsulating therapeutic enzymes within red blood cells to enhance their efficacy and reduce systemic side effects. The company's lead product candidate, eryaspase, is currently in Phase 3 clinical development for second-line pancreatic cancer and Phase 2 for other indications. ERYTECH aims to improve patient outcomes by providing novel therapies for unmet medical needs in oncology.

What do analysts say about ERYP stock?

Analyst coverage of ERYP is limited, reflecting its small-cap status and clinical-stage nature. However, analysts generally focus on the potential of eryaspase in addressing unmet needs in pancreatic cancer and other indications. Key valuation metrics include the potential market size for eryaspase, the probability of clinical trial success, and the likelihood of regulatory approval. Growth considerations include the company's ability to secure funding, expand its pipeline, and commercialize its products. Analyst consensus is pending further data from ongoing clinical trials. There is no consensus to buy or sell.

What are the main risks for ERYP?

The main risks for ERYP include the potential failure of clinical trials, particularly the Phase 3 trial for eryaspase in pancreatic cancer. Regulatory hurdles and delays in obtaining approval from health authorities also pose significant risks. Competition from established pharmaceutical companies with greater resources and broader pipelines could limit ERYP's market share. The company's dependence on the success of eryaspase, with limited diversification of its product pipeline, further increases its vulnerability. Securing sufficient funding to support ongoing research and development activities is also a critical risk.